PH12015500989A1 - Long-acting single-chain insulin analogues - Google Patents
Long-acting single-chain insulin analoguesInfo
- Publication number
- PH12015500989A1 PH12015500989A1 PH12015500989A PH12015500989A PH12015500989A1 PH 12015500989 A1 PH12015500989 A1 PH 12015500989A1 PH 12015500989 A PH12015500989 A PH 12015500989A PH 12015500989 A PH12015500989 A PH 12015500989A PH 12015500989 A1 PH12015500989 A1 PH 12015500989A1
- Authority
- PH
- Philippines
- Prior art keywords
- domain
- long
- ornithine
- histidine
- chain insulin
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 3
- 239000004475 Arginine Substances 0.000 abstract 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 abstract 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 2
- 239000004472 Lysine Substances 0.000 abstract 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 abstract 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 abstract 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 2
- 239000004026 insulin derivative Substances 0.000 abstract 2
- 229960003104 ornithine Drugs 0.000 abstract 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722350P | 2012-11-05 | 2012-11-05 | |
| PCT/US2013/068585 WO2014071405A2 (en) | 2012-11-05 | 2013-11-05 | Long-acting single-chain insulin analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12015500989A1 true PH12015500989A1 (en) | 2015-07-13 |
Family
ID=50628271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015500989A PH12015500989A1 (en) | 2012-11-05 | 2015-05-05 | Long-acting single-chain insulin analogues |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9499600B2 (enExample) |
| EP (1) | EP2914620B1 (enExample) |
| JP (1) | JP6584953B2 (enExample) |
| KR (1) | KR102163936B1 (enExample) |
| CN (2) | CN105008395B (enExample) |
| AU (1) | AU2013337250B2 (enExample) |
| BR (1) | BR112015010194B1 (enExample) |
| CA (1) | CA2890719C (enExample) |
| EA (1) | EA201590882A1 (enExample) |
| ES (1) | ES2694418T3 (enExample) |
| IL (1) | IL238651B (enExample) |
| MX (1) | MX2015005662A (enExample) |
| PH (1) | PH12015500989A1 (enExample) |
| SG (1) | SG11201503522RA (enExample) |
| WO (1) | WO2014071405A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014015078A1 (en) * | 2012-07-17 | 2014-01-23 | Michael Weiss | O-linked carbohydrate-modified insulin analogues |
| US9624287B2 (en) | 2012-07-17 | 2017-04-18 | Case Western Reserve University | O-linked carbohydrate-modified insulin analogues |
| WO2015106269A2 (en) | 2014-01-13 | 2015-07-16 | Thermalin Diabetes, Llc | Rapid action insulin formulations and pharmaceutical delivery systems |
| CZ308383B6 (cs) * | 2014-06-30 | 2020-07-15 | Ústav Organické Chemie A Biochemie Akademie Věd Čr, V.V.I. | Derivát inzulinu s cyklickou strukturou v C-konci B-řetězce |
| JP6829928B2 (ja) * | 2014-10-06 | 2021-02-17 | ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ | 二相性単鎖インスリン類似体 |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| HK1255634A1 (zh) * | 2015-12-23 | 2019-08-23 | Case Western Reserve University | 超稳胰岛素类似物在聚合物熔体中的包囊 |
| US20220002373A1 (en) * | 2018-11-19 | 2022-01-06 | Case Western Reserve University | Single-chain insulin analogues with poly-alanine c-domain sub-segments |
| CA3122636A1 (en) | 2018-12-11 | 2020-06-18 | Sanofi | Insulin analogs having reduced insulin receptor binding affinity |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| CN114867743A (zh) * | 2019-12-10 | 2022-08-05 | 赛诺菲 | 形成磺酰胺与多肽的缀合物的方法 |
| JP2024531773A (ja) | 2021-09-20 | 2024-08-29 | キュオン バイオテック アー・ゲー | アルギナーゼ－インスリン融合タンパク質 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE270306T1 (de) * | 2000-10-02 | 2004-07-15 | Univ Yonsei Seoul | Einkettige insulinanaloge |
| KR100449454B1 (ko) * | 2000-10-02 | 2004-09-21 | 이현철 | 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터 |
| CA2518776A1 (en) * | 2003-04-29 | 2004-11-11 | Eli Lilly And Company | Insulin analogs having protracted time action |
| KR100508616B1 (ko) * | 2003-06-20 | 2005-08-17 | 신항철 | 염기성 아미노산 첨가를 통한 활성이 증가된 단일사슬 인슐린 아날로그 |
| ES2369895T3 (es) * | 2003-12-03 | 2011-12-07 | Novo Nordisk A/S | Insulina monocatenaria. |
| WO2008043033A2 (en) * | 2006-10-04 | 2008-04-10 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
| NZ588857A (en) * | 2008-04-22 | 2012-07-27 | Univ Case Western Reserve | Isoform-specific insulin analogue for control blood sugar levels |
| WO2011003822A2 (de) * | 2009-07-06 | 2011-01-13 | Sanofi-Aventis Deutschland Gmbh | Insulinzubereitungen enthaltend methionin |
| JP2012532177A (ja) * | 2009-07-06 | 2012-12-13 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 熱及び振動安定性インスリン製剤 |
| US8399407B2 (en) | 2009-09-17 | 2013-03-19 | Case Western Reserve University | Non-standard insulin analogues |
| CN104010652A (zh) * | 2011-10-27 | 2014-08-27 | 卡斯西部储备大学 | 超浓缩的速效胰岛素类似物制剂 |
| JP2015507916A (ja) * | 2012-01-20 | 2015-03-16 | ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ | グルタミン酸安定化インスリン類似体 |
| CN108383902A (zh) * | 2012-09-26 | 2018-08-10 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物二聚体 |
-
2013
- 2013-11-05 KR KR1020157014591A patent/KR102163936B1/ko not_active Expired - Fee Related
- 2013-11-05 CN CN201380069346.0A patent/CN105008395B/zh not_active Expired - Fee Related
- 2013-11-05 MX MX2015005662A patent/MX2015005662A/es unknown
- 2013-11-05 JP JP2015541857A patent/JP6584953B2/ja not_active Expired - Fee Related
- 2013-11-05 EP EP13850542.5A patent/EP2914620B1/en active Active
- 2013-11-05 AU AU2013337250A patent/AU2013337250B2/en not_active Ceased
- 2013-11-05 EA EA201590882A patent/EA201590882A1/ru unknown
- 2013-11-05 WO PCT/US2013/068585 patent/WO2014071405A2/en not_active Ceased
- 2013-11-05 ES ES13850542.5T patent/ES2694418T3/es active Active
- 2013-11-05 SG SG11201503522RA patent/SG11201503522RA/en unknown
- 2013-11-05 CN CN202010947063.3A patent/CN112266414A/zh active Pending
- 2013-11-05 US US14/440,540 patent/US9499600B2/en not_active Expired - Fee Related
- 2013-11-05 BR BR112015010194-1A patent/BR112015010194B1/pt not_active IP Right Cessation
- 2013-11-05 CA CA2890719A patent/CA2890719C/en active Active
-
2015
- 2015-05-05 PH PH12015500989A patent/PH12015500989A1/en unknown
- 2015-05-05 IL IL238651A patent/IL238651B/en active IP Right Grant
-
2016
- 2016-11-22 US US15/358,977 patent/US9975940B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014071405A2 (en) | 2014-05-08 |
| JP2016506366A (ja) | 2016-03-03 |
| BR112015010194A2 (pt) | 2017-12-12 |
| MX2015005662A (es) | 2015-08-20 |
| WO2014071405A3 (en) | 2014-08-21 |
| CN112266414A (zh) | 2021-01-26 |
| KR102163936B1 (ko) | 2020-10-13 |
| JP6584953B2 (ja) | 2019-10-02 |
| CN105008395A (zh) | 2015-10-28 |
| IL238651A0 (en) | 2015-06-30 |
| BR112015010194B1 (pt) | 2022-03-22 |
| US9499600B2 (en) | 2016-11-22 |
| EP2914620B1 (en) | 2018-08-08 |
| CA2890719C (en) | 2023-02-14 |
| EP2914620A4 (en) | 2016-05-25 |
| ES2694418T3 (es) | 2018-12-20 |
| EP2914620A2 (en) | 2015-09-09 |
| AU2013337250B2 (en) | 2017-06-22 |
| CN105008395B (zh) | 2020-12-29 |
| IL238651B (en) | 2020-03-31 |
| US9975940B2 (en) | 2018-05-22 |
| US20170137488A1 (en) | 2017-05-18 |
| US20150274803A1 (en) | 2015-10-01 |
| EA201590882A1 (ru) | 2015-09-30 |
| CA2890719A1 (en) | 2014-05-08 |
| SG11201503522RA (en) | 2015-06-29 |
| KR20150096387A (ko) | 2015-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500989A1 (en) | Long-acting single-chain insulin analogues | |
| MY158627A (en) | Halogen-stabilized insulin | |
| JP2011241213A5 (enExample) | ||
| HRP20181026T1 (hr) | Dugodjelujuće formulacije inzulina | |
| MY167234A (en) | Novel glucagon analogues | |
| MX2013011175A (es) | Analogos de glucagon novedosos. | |
| EA201692159A1 (ru) | Композиция для лечения диабета, содержащая конъюгат на основе аналога инсулина длительного действия и конъюгат на основе аналога инсулинотропного пептида длительного действия | |
| PH12012501135A1 (en) | Insulin analogues with chlorinated amino acids | |
| NZ625391A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
| NZ611878A (en) | Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides | |
| RU2012157683A (ru) | Производные инсулина, содержащие дополнительные дисульфидные связи | |
| NZ600477A (en) | Insulin analogues with chlorinated amino acids | |
| MX336412B (es) | Nuevos analogos de glucagon. | |
| MX366314B (es) | Uso de derivados de insulina por inyecciones con intervalos variables. | |
| JP2014169326A5 (enExample) | ||
| MX2013008484A (es) | Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2. | |
| RU2014126244A (ru) | Лекарственные средства, содержащие аминокислотные последовательности инсулина | |
| GEP20176629B (en) | Glucagon/glp-1 receptor co-agonists | |
| RU2012122162A (ru) | Гликолизированная форма аналога антигенного glp-1 | |
| MY181626A (en) | Treatment of diabetes mellitus by long-acting formulations of insulins | |
| WO2015105981A3 (en) | Nutritional composition comprising hmb for increasing or maintaining lean body mass in subjects having reduced leucine to hmb conversion efficiency or undergoing diabetic treatment | |
| JP2013530974A5 (enExample) | ||
| JP2013530702A5 (enExample) | ||
| EP3404029A3 (en) | Pyrimido-pyridazinone compounds and methods and use thereof | |
| JP2012511506A5 (enExample) |